
Feb 13 (Reuters) - Disc Medicine Inc IRON.O:
DISC MEDICINE RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR BITOPERTIN FOR THE TREATMENT OF EPP
DISC MEDICINE INC - FDA REQUIRES RESULTS FROM PHASE 3 APOLLO STUDY FOR DECISION
DISC MEDICINE INC - PHASE 3 APOLLO STUDY TOPLINE DATA EXPECTED Q4 2026
DISC MEDICINE INC: FDA ACKNOWLEDGED THAT AURORA AND BEACON PROVIDED SUFFICIENT EVIDENCE THAT BITOPERTIN SIGNIFICANTLY LOWERS PPIX
DISC MEDICINE INC: EXPECT AN UPDATED FDA DECISION BY MID-2027
DISC MEDICINE INC: PLANS TO REQUEST A TYPE A MEETING TO REVIEW OUR APPROACH WITH FDA